Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

biotoscana farma de peru s.a.c. - azacitidina; - polvo para solucion inyectable - por vial - azacitidina

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

accord healthcare s.a.c. - droguerÍa - azacitidina; - polvo para suspension inyectable - por vial mg - - azacitidina

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

bristol-myers squibb peru s.a. - droguerÍa - polvo para suspension inyectable - por vial - - azacitidina

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

advance scientific del peru s.a.c. - droguerÍa - polvo para suspension inyectable - por vial - - azacitidina

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

global med farma s.a.c. - droguerÍa - polvo para concentrado para solucion para perfusion - por vial - - azacitidina

Unión Europea - español - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - azacitidina - leucemia, mieloide, aguda - agentes antineoplásicos - onureg is indicated as maintenance therapy in adult patients with acute myeloid leukaemia (aml) who achieved complete remission (cr) or complete remission with incomplete blood count recovery (cri) following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, hematopoietic stem cell transplantation (hsct).

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

perulab s.a. - droguerÍa - azacitidina; - polvo para solucion inyectable - por vial 1.00 - - azacitidina

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

mega labs latam s.a. - azacitidina; - polvo para solucion inyectable - por vial - azacitidina

Unión Europea - español - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - azacitidina - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - agentes antineoplásicos - vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with: intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification. vidaza is indicated for the treatment of adult patients aged 65 years or older who are not eligible for hsct with aml with >30% marrow blasts according to the who classification.

Unión Europea - español - EMA (European Medicines Agency)

celgene europe bv - azacitidina - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - agentes antineoplásicos - azacitidine celgene is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification,aml with >30% marrow blasts according to the who classification.